Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / COM
-
Number of holders
-
24
-
Total 13F shares, excl. options
-
1,267,676
-
Shares change
-
+118,188
-
Total reported value, excl. options
-
$5,679,140
-
Value change
-
+$520,599
-
Put/Call ratio
-
73.27%
-
Number of buys
-
15
-
Number of sells
-
-5
-
Price
-
$4.48
Significant Holders of Gain Therapeutics, Inc. - COM (GANX) as of Q2 2023
30 filings reported holding GANX - Gain Therapeutics, Inc. - COM as of Q2 2023.
Gain Therapeutics, Inc. - COM (GANX) has 24 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1,267,676 shares
.
Largest 10 shareholders include GREENLIGHT CAPITAL INC (546,560 shares), GEODE CAPITAL MANAGEMENT, LLC (138,721 shares), CM Management, LLC (90,000 shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (69,790 shares), VANGUARD GROUP INC (64,118 shares), PRELUDE CAPITAL MANAGEMENT, LLC (58,100 shares), RENAISSANCE TECHNOLOGIES LLC (47,600 shares), BRIDGEWAY CAPITAL MANAGEMENT, LLC (46,100 shares), CITADEL ADVISORS LLC (36,247 shares), and RAYMOND JAMES & ASSOCIATES (33,400 shares).
This table shows the top 24 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.